Diagnostic Performance of Urinary Keratin 17 Immunocytochemistry (URO17®) During Hematuria Evaluation: A Retrospective Study
Diagnostics · 18.11.2026 · 16 (22) · 3846
DOI: 10.3390/diagnostics16223846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 18.11.2026. Verfasst von Sasha Homayoun und 9 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Urinary biomarkers may assist hematuria risk stratification, but diagnostic performance must be assessed against an appropriate reference standard. We evaluated urinary keratin 17 immunocytochemistry (URO17®) during hematuria evaluation and compared it with urine cytology.
Methods
This retrospective, single-center study included adults evaluated between August 2019 and March 2026. The analytic cohort comprised 746 specimens from 612 patients. Formal diagnostic accuracy analyses used one result-independently selected specimen per patient in the reference-standard cohort. URO17® positivity was defined as at least 10 keratin 17-positive cells. Sensitivity and specificity were compared using paired McNemar tests; atypical cytology was classified as negative in the primary comparison.
Results
The reference-standard analysis included 313 patients, including 20 with histopathologically confirmed urothelial carcinoma. URO17® sensitivity was 90.0% (95% confidence interval, 69.9–97.2), specificity 90.1% (86.1–93.0), and negative predictive value 99.2% (97.3–99.8). Cytology sensitivity was 20.0% and specificity 98.6%. URO17® was 70.0 percentage points more sensitive and 8.5 percentage points less specific (both p < 0.001). Quantitative cell counts yielded an area under the receiver operating characteristic curve of 0.938. Patients without reference-standard verification were analyzed descriptively.
Conclusions
URO17® demonstrated higher sensitivity but lower specificity than conventional cytology when atypical cytology was classified as negative. The high negative predictive value reflects, in part, the 6.4% cancer prevalence in the verified cohort. Selective verification and the small number of cancer-positive patients limit interpretation. Prospective multicenter validation is needed to define its adjunctive clinical role.
Zitieren
APA
Homayoun, S., Bisen, A., Jahanfard, C., Nudell, D., Noller, D., Noller, M., Jahanfard, S., Kim, N. W., Lotan, Y., & Gholami, S. S. (2026). Diagnostic Performance of Urinary Keratin 17 Immunocytochemistry (URO17®) During Hematuria Evaluation: A Retrospective Study. Diagnostics, 16(22), 3846. https://doi.org/10.3390/diagnostics16223846
Vancouver
Homayoun S, Bisen A, Jahanfard C, Nudell D, Noller D, Noller M, et al. Diagnostic Performance of Urinary Keratin 17 Immunocytochemistry (URO17®) During Hematuria Evaluation: A Retrospective Study. Diagnostics. 2026;16(22):3846. doi:10.3390/diagnostics16223846
BibTeX
@article{Homayoun2026,
author = {Homayoun, Sasha and Bisen, Anamika and Jahanfard, Chelgis and Nudell, David and Noller, David and Noller, Mark and Jahanfard, Sholeh and Kim, Nam W. and Lotan, Yair and Gholami, Shahram Shawn},
title = {Diagnostic Performance of Urinary Keratin 17 Immunocytochemistry (URO17®) During Hematuria Evaluation: A Retrospective Study},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {22},
pages = {3846},
doi = {10.3390/diagnostics16223846}
}
EUVIMED